Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may reveal who benefits from ED drug

NCT ID NCT07479901

Knowledge-focused Sponsor: Taksim Egitim ve Arastirma Hastanesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study looks at whether a blood test measuring the 'atherogenic index' can predict how well the drug tadalafil works for men with erectile dysfunction caused by blood vessel problems. Researchers will give 132 men tadalafil daily for one month and compare their symptom scores before and after treatment. The goal is to see if this simple blood marker can help personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tadalafil
What this could lead to
If successful, this could help doctors predict which men with erectile dysfunction will respond best to tadalafil based on a simple blood test.
What could go wrong
This is a small, observational study, not a large trial. The link between the blood marker and treatment response may not be strong enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

176 people

The number who actually took part.

Started

Apr 2025

Finished

Feb 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men aged 40 years or older presenting consecutively to the outpatient urology clinic with erectile dysfunction symptoms for at least 3 months, an IIEF-EF score below 26, and predominantly vasculogenic erectile dysfunction based on clinical assessment were enrolled. Tadalafil 5 mg orally once daily was prescribed as part of routine clinical care, independently of study participation, and participants were prospectively followed for 12 weeks. Patients with contraindications to tadalafil, major nonvasculogenic causes of erectile dysfunction, or predefined unstable systemic or metabolic conditions were excluded.

Ages

40 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Men aged 40 years or older Erectile dysfunction symptoms for at least 3 months International Index of Erectile Function-Erectile Function domain (IIEF-EF) score below 26 Predominantly vasculogenic erectile dysfunction based on medical history, focused physical examination, and baseline clinical assessment Suitable for tadalafil treatment Phosphodiesterase type 5 inhibitor-naive or no phosphodiesterase type 5 inhibitor use for at least 1 month before enrollment Provided written informed consent Exclusion Criteria: Contraindication to tadalafil, including nitrate use Major cardiovascular disease within the previous 6 months or other clinically unstable cardiovascular conditions Diagnosed hypogonadism or hormone replacement therapy Severe hepatic or renal insufficiency Predominantly psychogenic erectile dysfunction Erectile dysfunction primarily attributable to neurological, hormonal, or medication-related causes Previous radical pelvic surgery or major pelvic trauma Penile anatomical abnormalities, including Peyronie's disease Alcohol or substance dependence Poorly controlled diabetes mellitus, defined as glycated hemoglobin (HbA1c) of 8.0% or higher Use of medications affecting lipid metabolism, such as corticosteroids Initiation or dose modification of lipid-lowering therapy within the previous 3 months Uncontrolled thyroid dysfunction Active infection or inflammatory disease Active malignancy treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erectile dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

erectile dysfunction vasculogenic impotence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erectile dysfunction Erectile dysfunction vascular erectile dysfunction atherogenic dyslipidemia

Contacts and locations

Locations

  • Taksim Training and Research Hospital

    Istanbul, Istanbul, 34433, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.